Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes

globenewswire.com
PFE Pfizer Inc. is mentioned as a prominent company in the neuroblastoma market, which is experiencing significant growth due to rising childhood cancer incidence and advancements in treatment. The article does not provide specific details on Pfizer's performance or outlook within this market. LLY Eli Lilly and Company is listed as a prominent company in the growing neuroblastoma market. The article highlights the overall market expansion driven by increased cancer incidence and treatment innovations, but offers no specific sentiment or details regarding Eli Lilly's direct involvement or performance. MGNX MacroGenics Inc. is identified as a company operating within the expanding neuroblastoma market. The article focuses on the overall market growth drivers, such as increased cancer cases and treatment advancements, without providing specific sentiment or performance data for MacroGenics. LGND Ligand Pharmaceuticals Inc. is presented positively due to its acquisition of Apeiron Biologics AG, enhancing its portfolio with royalty rights to immunotherapies like Qarziba, which are relevant to the growing neuroblastoma market.

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Neuroblastoma Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The neuroblastoma market has witnessed significant growth, projected to expand from $3.14 billion in 2025 to $3.32 billion in 2026, with a CAGR of 5.8%. Factors driving this growth include an increase in pediatric neuroblastoma cases and advancements in treatment modalities, including chemotherapy and immunotherapy vaccines. Clinical diagnostic capabilities have also improved, leading to better early detection and heightened awareness of childhood cancer symptoms.

Looking ahead, the neuroblastoma market is set to continue its upward trajectory, reaching $4.12 billion by 2030 at a CAGR of 5.5%. This growth is bolstered by ongoing research in targeted therapy, increased investments in cell therapy products, and adoption of precision oncology methods. Innovations such as advanced diagnostic imaging and pediatric immunotherapy solutions are key contributors. Emerging trends include the adoption of immunotherapy vaccines, targeted oral chemotherapy, and monoclonal antibody treatments, alongside advances in regenerative oncology.

The increasing incidence of childhood cancers, including neuroblastoma, is a primary market driver. Improved diagnostic methods and greater awareness, coupled with genetic and environmental factors, contribute to rising case numbers. In the United States, an estimated 9,620 children under 15 are expected to be diagnosed with cancer in 2024, an increase from 5,290 in 2023, according to the American Cancer Society. This reality underscores the critical need for targeted therapies that improve outcomes and reduce recurrence risks.

Key industry players are advancing therapeutic interventions; for instance, Renaissance Pharma Ltd. has in-licensed Hu14.18K322A from St. Jude Children's Research Hospital, targeting high-risk neuroblastoma with humanized anti-GD2 monoclonal antibodies. Similarly, Ligand Pharmaceuticals Inc. acquired Apeiron Biologics AG, enhancing its portfolio with royalty rights to high-value immunotherapies like Qarziba.

Prominent companies in this sector include Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, and others like MacroGenics Inc. and Y-mAbs Therapeutics Inc. While North America dominated the market in 2025, the Asia-Pacific region is anticipated to lead growth rates moving forward.

This comprehensive neuroblastoma market research report provides vital insights, offering detailed analysis of market size, regional shares, trends, and opportunities for industry stakeholders.

Reasons to Purchase:

Report Scope:

Key Attributes

The companies featured in this Neuroblastoma market report include:

For more information about this report visit https://www.researchandmarkets.com/r/76s5je

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment